|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 14, 2016 ) Dermatophytes cause fungal infections of keratinized tissues, e.g. skin, hair and nails. The organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum. Dermatophytes may be grouped into 3 categories based on host preference and natural habitat. Anthropophilic species predominantly infect humans, geophilic species are soil based and may infect both humans and animals, zoophilic species generally infect non-human mammals.
Report Summary:
The report provides comprehensive information on the therapeutics under development by Soligenix, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this report at http://www.reportsweb.com/soligenix-inc-product-pipeline-review-2016
Scope:
- The report provides a snapshot of the pipeline therapeutic landscape of Soligenix, Inc.
- The report provides overview of Soligenix, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Soligenix, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Soligenix, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001372854/sample
Reasons to buy:
- Evaluate Soligenix, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Soligenix, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soligenix, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001372854/discount
List of Tables
Soligenix, Inc., Key Information 5
Soligenix, Inc., Key Facts 5
Soligenix, Inc. - Pipeline by Indication, 2016 7
Soligenix, Inc. - Pipeline by Stage of Development, 2016 9
Soligenix, Inc. - Monotherapy Products in Pipeline, 2016 10
Soligenix, Inc. - Combination Treatment Modalities in Pipeline, 2016 11
Soligenix, Inc. - Phase III, 2016 12
Soligenix, Inc. - Phase II, 2016 13
Soligenix, Inc. - Phase I, 2016 14
Soligenix, Inc. - IND/CTA Filed, 2016 15
Soligenix, Inc. - Preclinical, 2016 16
Soligenix, Inc. - Pipeline by Target, 2016 30
Soligenix, Inc. - Pipeline by Route of Administration, 2016 31
Soligenix, Inc. - Pipeline by Molecule Type, 2016 32
Soligenix, Inc. - Pipeline Products by Mechanism of Action, 2016 33
Soligenix, Inc. - Recent Pipeline Updates, 2016 34
Soligenix, Inc. - Dormant Developmental Projects,2016 44
Soligenix, Inc. - Discontinued Pipeline Products, 2016 45
Soligenix, Inc., Subsidiaries 46
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
